Florida Atlantic University, Boca Raton, Florida.
Siperstein Dermatology Group, Boynton Beach, Florida.
Dermatol Surg. 2024 Dec 1;50(12):1143-1148. doi: 10.1097/DSS.0000000000004315. Epub 2024 Jul 5.
Hyaluronic acid (HA) filler longevity has been studied for wrinkles. However, its long-term use for treating atrophic facial scars has not yet been analyzed in long-term prospective studies.
Analyze the safety and duration of a HA filler for the use in atrophic scars.
Fifteen subjects received VYC-17.5L in atrophic scars on 1 randomized cheek and saline on the other, with 1 optional touch-up treatment and crossover after the short-term trial. Grading for this long-term extension was done on Day 720, using the Global Aesthetic Improvement Scale (GAIS) and the Quantitative Global Scarring Grading System.
On Day 720, a live blind evaluator rated the VYC-17.5L assigned side as having significant reduction in scar severity (-7.2 [t(22) = -6.01, p = .00009]) and number of scars (-8.8 [t(22) = -6.25, p = .00006]) as compared with baseline. There was no significant difference in the results from Day 120 to Day 720. Ninety-two percent (11/12) of subjects reported improvement (GAIS), were satisfied with the treatment, thought it looked natural, and had fewer side effects than expected. There were no persistent or late-onset side effects.
VYC-17.5L improved rolling atrophic facial scars, and the results were sustained throughout the 2-year trial without side effects.
已有研究分析了透明质酸（HA）填充剂在皱纹方面的长效性，但尚未对其长期用于治疗萎缩性面部瘢痕进行长期前瞻性研究。
分析 HA 填充剂治疗萎缩性瘢痕的安全性和持久性。
15 名受试者随机在一侧面颊接受 VYC-17.5L 治疗，另一侧接受生理盐水治疗，在短期试验后进行了 1 次可选的追加治疗和交叉。在第 720 天，使用全球美学改善量表（GAIS）和定量整体瘢痕分级系统对长期扩展进行分级。
在第 720 天，一位盲法活体评估员对 VYC-17.5L 治疗侧的瘢痕严重程度评分（-7.2 [t(22) = -6.01，p =.00009]）和瘢痕数量评分（-8.8 [t(22) = -6.25，p =.00006]）与基线相比有显著降低。从第 120 天到第 720 天，结果没有显著差异。92%（11/12）的受试者报告改善（GAIS），对治疗满意，认为效果自然，且副作用比预期少。没有持续或迟发性副作用。
VYC-17.5L 改善了滚动性萎缩性面部瘢痕，并且在 2 年的试验中没有副作用，结果持续存在。
